Silent cerebral infarction in patients with type 2 diabetic nephropathy. Effects of antiplatelet drug dilazep dihydrochloride

Nakamura, Tsukasa; Kawagoe, Yasuhiro; Matsuda, Takemasa; Ueda, Yoshihiko; Ebihara, Isao; Koide, Hikaru

doi:10.1002/dmrr.473

Cited by 14 publications

(10 citation statements)

References 24 publications

(32 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This differs from the results obtained by Nakamura and his colleague [16] who found that 20% had silent cerebral infarction. This difference could be due to differences in study design, sample size or the degree of disease progression before the MRI brain scan was conducted.…”

Section: Discussioncontrasting

confidence: 98%

Silent Cerebral Infarctions in Type II Diabetes Mellitus Patients; Could Brain MRI Be a Routine Investigation?

Ibrahim¹,

Alloush²,

Shaaban³

et al. 2014

OJMI

View full text Add to dashboard Cite

Objective: To study the prevalence of silent cerebral infarction in Type II diabetes mellitus. Patients and Methods: The study was a prospective on 80 patients recruited from neurology, endocrine outpatient clinics. Patients were type II diabetics as described by the American Diabetes Association, 2011 criteria. All patients underwent full metabolic profiles to diagnose diabetes mellitus and MRI brain scans to detect cerebral infarction. Results: Silent cerebral infarctions were detected in 60% of patients (48/80 patients) predominately along periventricular white matter area and subcortical areas (Basal ganglia, Thalamus). Conclusion: Asymptomatic Type II diabetes mellitus patients could have vascular cerebral changes without neurological symptoms. MRI brain scans could be recommended as routine diagnosis (if possible) for early cerebral infarct detection in type II diabetic patients.

show abstract

Section: Discussioncontrasting

confidence: 98%

Silent Cerebral Infarctions in Type II Diabetes Mellitus Patients; Could Brain MRI Be a Routine Investigation?

Ibrahim¹,

Alloush²,

Shaaban³

et al. 2014

OJMI

View full text Add to dashboard Cite

show abstract

“…None of the patients had been given antihypertensive drugs, including angiotensin-converting enzyme inhibitor or angiotensin receptor blocker, or antiplatelet drugs, i.e. drugs reported to be renoprotective [9,10]. There was no malignancy, heart disease, cerebrovascular disease, liver disease, or collagen disease, according to a physical examination and urine and blood test results and radiography, electrocardiography, ultrasound cardiography, or X-ray computed tomography data.…”

Section: Methodsmentioning

confidence: 98%

Effect of pioglitazone on urinary liver‐type fatty acid‐binding protein concentrations in diabetes patients with microalbuminuria

Nakamura

Sugaya²,

Kawagoe

et al. 2006

Diabetes Metabolism Res

Self Cite

View full text Add to dashboard Cite

show abstract

“…However, since only CT was used in this study for the detection of SBI, the validity of its findings is doubtful as CT is insensitive for detection of small brain infarcts. In two small open-labeled randomized controlled studies using antithrombotic agents (cilostazol, n = 89; dilazep hydrochloride, n = 30) among diabetic patients, the incidence of SBI was significantly lower in the active group than in the placebo group over 2–3 years [25,26]. …”

Section: Discussionmentioning

confidence: 99%

Effects of Statins on Progression of Subclinical Brain Infarct

Mok

Lam

et al. 2010

Cerebrovasc Dis

View full text Add to dashboard Cite

Background: Subclinical brain infarct (SBI) is associated with subsequent stroke and cognitive decline. A longitudinal epidemiological study suggests that statins may prevent development of SBI. We investigated the effects of statins upon development of brain infarct by performing a post-hoc analysis of the Regression of Cerebral Artery Stenosis (ROCAS) study. Methods: The ROCAS study is a randomized, double-blind, placebo-controlled study evaluating the effects of simvastatin 20 mg daily upon progression of asymptomatic middle cerebral artery stenosis among stroke-free individuals over 2 years. A total of 227 subjects were randomized to either placebo (n = 114) or simvastatin 20 mg daily (n = 113). The number of brain infarcts as detected by MRI was recorded at baseline and at the end of the study. The primary outcome measure was the number of new brain infarcts at the end of the study. Results: Among the 227 randomized subjects, 33 (14.5%) had SBI at baseline. At the end of the study, significantly fewer subjects in the active group (n = 1) had new brain infarcts compared with the placebo group (n = 8; p = 0.018). The new brain infarcts of subjects in the active group were subclinical. Among the placebo group, the new brain infarcts of 3 subjects were symptomatic while those of the remaining 5 subjects were subclinical. Among putative variables, multivariate regression analysis showed that only the baseline number of SBIs (OR = 6.27, 95% CI 2.4–16.5) and simvastatin treatment (OR = 0.09, 95% CI 0.01–0.82) independently predicted the development of new brain infarcts. Conclusions: Consistent with findings of the epidemiological study, our study suggests that statins may prevent the development of a new brain infarct.

show abstract

Silent cerebral infarction in patients with type 2 diabetic nephropathy. Effects of antiplatelet drug dilazep dihydrochloride

Abstract: These data suggest that diabetic renal dysfunction increases the risk of silent cerebral infarction and that dilazep dihydrochloride prevents its onset in early type 2 diabetic nephropathy patients.

Cited by 14 publications

References 24 publications

Silent Cerebral Infarctions in Type II Diabetes Mellitus Patients; Could Brain MRI Be a Routine Investigation?

Silent Cerebral Infarctions in Type II Diabetes Mellitus Patients; Could Brain MRI Be a Routine Investigation?

Effect of pioglitazone on urinary liver‐type fatty acid‐binding protein concentrations in diabetes patients with microalbuminuria

Effects of Statins on Progression of Subclinical Brain Infarct

Contact Info

Product

Resources

About